Hurdles and delays in access to anti-cancer drugs in Europe

Area of Science:

• Oncology
• Health Services Research
• Pharmaceutical Sciences

Background:

• Global demographic changes are projected to increase cancer incidence.
• Innovative anticancer drugs are crucial for managing the growing cancer burden.
• Current clinical practice faces significant hurdles in adopting new cancer therapies.

Purpose of the Study:

• To provide a comprehensive overview of the anticancer drug development and implementation process.
• To identify and discuss the obstacles encountered at each stage of bringing innovative drugs into clinical practice.
• To inform strategies for optimizing patient treatment and facilitating health innovation.

Main Methods:

• Systematic review of the drug development and regulatory approval pathways.
• Analysis of factors influencing physician prescription habits and patient compliance.
• Examination of economic and policy-related barriers to drug uptake.

Main Results:

• The journey from drug discovery to routine clinical use is lengthy and involves multiple stakeholders.
• Key hurdles include regulatory approval, reimbursement negotiations, physician behavior change, and patient adherence.
• Successful implementation requires a coordinated approach across research, industry, healthcare providers, and policymakers.

Conclusions:

• Addressing the challenges in anticancer drug implementation is critical for improving patient outcomes amidst rising cancer rates.
• A clear understanding of the entire process, including its bottlenecks, is essential for effective health innovation.
• Strategies targeting regulatory, economic, and behavioral factors are needed to accelerate the adoption of novel cancer treatments.